The role of fibrin glue instillation under skin flaps in the prevention of seroma formation and related morbidities following breast and axillary surgery for breast cancer: A meta-analysis

2012 ◽  
Vol 106 (6) ◽  
pp. 783-795 ◽  
Author(s):  
Muhammad S. Sajid ◽  
Kristian Hutson ◽  
Lorain Kalra ◽  
Riccardo Bonomi
Author(s):  
Nunzio Velotti ◽  
Gennaro Limite ◽  
Antonio Vitiello ◽  
Giovanna Berardi ◽  
Mario Musella

AbstractSeroma formation following mastectomy is one of the most experienced complications, with a very variable incidence ranging from 3 to 90%. In recent years, many publications have been realized to define an effective technique to prevent its formation and several approaches have been proposed. Given the potential of flap fixation in reducing seroma formation, we performed a meta-analysis of the literature to investigate the role of this approach as definitive gold standard in mastectomy surgery. Inclusion criteria regarded all studies reporting on breast cancer patients undergoing mastectomy with or without axillary lymph node dissection; studies that compared mastectomy with flap fixation to mastectomy without flap fixation were selected. Papers were eligible for inclusion if outcome was described in terms of seroma formation. As secondary outcome, also surgical site infection (SSI) was evaluated. The included studies were 12, involving 1887 female patients: 221/986 (22.41%) patients experienced seroma formation after flap fixation and 393/901 (43.61%) patients had this complication not receiving flap fixation, with a significant statistical difference between the two groups (OR = 0.267, p = 0.001, 95% CI 0.153, 0.464). About, SSI 59/686 (8.6%) in flap fixation group and 67/686 (9.7%) in patients without flap fixation, with no statistical differences between groups (OR = 0.59, p = 0.056, 95% CI 0.344, 1.013).The heterogeneity between included studies does not allow us to reach definitive conclusions but only to suggest the strong evaluation of this approach after mastectomy in seroma preventing and SSI reduction.


2015 ◽  
Vol 52 (7) ◽  
pp. 153
Author(s):  
S Ma ◽  
D Wang ◽  
Y Shi ◽  
N Li ◽  
H Ren ◽  
...  

2020 ◽  
Vol 48 (10) ◽  
pp. 030006052096434
Author(s):  
Zhen-Yu Li ◽  
Zhen Zhang ◽  
Xiao-Zhong Cao ◽  
Yun Feng ◽  
Sha-Sha Ren

Background Triple-negative breast cancer (TNBC) is associated with higher aggressiveness and mortality than hormone-positive breast cancer because of the lack of approved therapeutic targets. Patients with TNBC who attain a pathological complete response (pCR) after neoadjuvant chemotherapy have improved survival. Platinum-based agents show promising activity in TNBC; however, their use remains controversial. We conducted a meta-analysis to assess the role of platinum-based agents in neoadjuvant chemotherapy in patients with TNBC. Methods We performed an extensive literature search of the Pubmed, Embase, and Cochrane databases. We calculated pooled odds ratios (OR) with 95% confidence intervals (CI) for the identified studies. Results Eight randomized controlled trials with 1345 patients were included in the analysis. The addition of platinum-based agents improved pCR compared with neoadjuvant therapy based on anthracyclines, cyclophosphamide, taxanes, and fluorouracil (49.1% vs. 35.9%; OR: 1.87, 95% CI: 1.23–2.86). Hematological adverse events were similar in both groups, except for more thrombocytopenia in the platinum-based group (OR: 7.96, 95% CI: 3.18–19.93). Conclusion The addition of platinum-based agents to neoadjuvant chemotherapy improved pCR rates in patients with TNBC, with a slight increase in hematological toxicities. Platinum-based agents might thus be an accessible and economically viable option in patients with TNBC.


2010 ◽  
Vol 101 (7) ◽  
pp. 600-603 ◽  
Author(s):  
Calogero Cipolla ◽  
Salvatore Fricano ◽  
Salvatore Vieni ◽  
Giuseppa Graceffa ◽  
Gaspare Licari ◽  
...  

2011 ◽  
Vol 130 (3) ◽  
pp. 809-816 ◽  
Author(s):  
Shu Zhao ◽  
Yupeng Liu ◽  
Qingyuan Zhang ◽  
Hongbin Li ◽  
Minghui Zhang ◽  
...  

2016 ◽  
Vol In press (In press) ◽  
Author(s):  
Bibi Hajar Zahmatkesh ◽  
Afsaneh Keramat ◽  
Nasrinossadat Alavi ◽  
Ahmad Khosravi ◽  
Reza Chaman

Author(s):  
Akhil Jain ◽  
Moushumi Suryavanshi ◽  
Ullas Batra ◽  
Pankaj Goyal ◽  
Dinesh Doval

<span>Breast cancer is a heterogeneous disease. Liquid biopsy is a novel diagnostic tool and may provide answers to many questions related to unevenness in prognosis and ultimate outcome. Different technologies for CTC isolation, enrichment, detection, and characterization are under evaluation. Various clinical trials and meta-analysis have been conducted to define the role of CTC in early and metastatic breast cancer. CTCs are superior to other serum markers for prognostication. Their role as predictive marker remains elusive.</span>


2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 1050-1050
Author(s):  
Rodrigo Ramella Munhoz ◽  
Allan Andresson Lima Pereira ◽  
Andre Deeke Sasse ◽  
Paulo Marcelo Hoff ◽  
Tiffany A. Traina ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document